The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Venture capitalists put more skin in fewer deals during the 1st quarter, amid an overall decline in life science deals, according to a survey of VC shops.
The number of deals for the medical device & equipment sector dropped 37% to 61 transactions, but the total value of those deals rose 28% to $588 million, according to the MoneyTree report from PricewaterhouseCoopers LLP and the National Venture Capital Assn., based on data provided by Thomson Reuters.
High levels of life sciences mergers and acquisitions in the tail-end of 2013 may make for a busy start to 2014, according to a report from PricewaterhouseCoopers.
Total deal volume in the medical device industry contracted by about 13% in 2013, according to new analysis from audit shop PricewaterhouseCoopers.
Healthcare industry analysts at PricewaterhouseCoopers’ Health Research Institute have a few lessons for companies navigating what promises to be a turbulent year ahead, offering advice ranging from failing frugally to adapting to heightened transparency expectations.
Here are 3 of the most relevant foresights for the medical device industry, selected from HRI’s top 10:
There has been much recent hand-wringing about the lack of availability of funding for medtech startup, but analysts at PricewaterhouseCoopers see it a little differently.
Third-quarter investment in medical device companies by venture capital shops was down, but the value of the deals rose, according to the PricewaterhouseCoopers/National Venture Capital Assn. MoneyTree report.
The report, which uses data compiled by Thompson Reuters, found that the 65 medtech deals inked by VCs during the 3 months ended Sept. 30 was down 8% compared with the 2nd quarter. But the value of those deals, pegged at $566 million, rose 12% compared with Q2, according to the report.
There was good news and bad news in the latest life sciences deals report from the analysts at PricewaterhouseCoopers. Investment in the medical device industry took a hard downward turn year-over-year, but market trends signal that the life sciences market may expect a comeback before the end of 2013.
MASSDEVICE ON CALL — A U.S. House of Representatives committee slammed the FDA over the $1 billion in unobligated user fees the watchdog agency is carrying on its books.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
The number of medical device merger & acquisition deals and their value fell during the 1st quarter, according to PricewaterhouseCoopers, but that doesn’t mean there wasn’t a lot of activity behind the scenes, Dimitri Drone, leader of PricewaterhouseCoopers’ Transaction Services Life Sciences sector, told MassDevice.com.
As the Chinese healthcare market grows at an unprecedented clip, investors should concentrate on a handful of opportunities that take advantage of economic and regulatory trends in the alluring emerging market, a new report from PricewaterhouseCoopers says.
